22nd Century Group, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90137F2020
USD
1.05
-0.01 (-0.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About 22nd Century Group, Inc. stock-summary
stock-summary
22nd Century Group, Inc.
Pharmaceuticals & Biotechnology
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.
Company Coordinates stock-summary
Company Details
8560 Main St Ste 4 , WILLIAMSVILLE NY : 14221-7435
stock-summary
Tel: 1 716 2701523
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 9 Schemes (0.27%)

Foreign Institutions

Held by 12 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Nora Sullivan
Chairman of the Board
Dr. Michael Koganov
Independent Director
Mr. Roger O'Brien
Independent Director
Mr. Richard Sanders
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.19

stock-summary
Return on Equity

-254.14%

stock-summary
Price to Book

1.09